Publication | Open Access

Selective EZH2 inhibitor zld1039 alleviates inflammation in cisplatin-induced acute kidney injury partially by enhancing RKIP and suppressing NF-κB p65 pathway

InflammationCytokineAnti-inflammatoryMedicineImmunologyRenal InflammationChronic InflammationNf-κb P65 PathwayCell BiologyAcute Kidney InjuryEpigenetic RegulationInflammatory DiseaseCell SignalingMolecular Signaling